CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
Erlotinib +1 moredrug
Likely dose
Erlotinib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00367601
NCT00367601Phase 2Completed
CompareCT.gov

A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer

Nasser Hanna, M.D.·interventional·Posted Aug 23, 2006·Updated Feb 11, 2016

In Brief

A Phase 2 clinical trial evaluating Erlotinib and Bevacizumab for Lung Cancer. Completed, enrolled 25 participants across 13 sites.

Detailed Summary

The strategy for combining therapeutic agents in cancer treatments has been successful in multiple tumor types, including NSCLC. Erlotinib and bevacizumab target different pathways involved in tumor growth. Nonclinical studies have demonstrated that the combination of bevacizumab and erlotinib results in greater efficacy than either agent alone. Furthermore, because there is little to no overlap in toxicity profile between the two agents, the combination is expected to be well tolerated and may provide even greater benefit for patients who are unable to receive cytotoxic therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsGenentech, Inc., Walther Cancer Institute, Hoosier Cancer Research Network

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 23, 2006
Enrollment StartAug 1, 2006
Primary CompletionApr 1, 2008
Study CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 19.9 years ago

Interventions

Erlotinibdrug

Erlotinib 150 mg qd days 1-21

Bevacizumabdrug

Bevacizumab 15 mg/kg IV, day 1